Oncologic Emergencies Part 2 Flashcards
Tumor Lysis Syndrome Risk Factors
Tumor with high proliferative rate Tumor sensitive to cytotoxic therapy Large tumor masses Leukocytosis High LDH Pre-existing renal insufficiency Hematologic malignancies
LDH + Tumor Lysis
Indirect measurement of patient’s tumor burden
Tumors sensitive to cytotoxic therapy –>
Tumors that are more sensitive will have more dying and releasing of components
Highest Risk of TLS
Burkitt’s lymphoma
Lymphoblastic lymphoma
ALL
AML
Moderate Risk of TLS
Multiple myeloma
Breast cancer
Small cell lung
Germ cell
What is Tumor Lysis Syndrome
Rapid lysis of tumor cells leads to release of intracellular content which leads to exceeding ability for normal compensatory mechanisms
Findings with TLS
Hyperuricemia
Hyperkalemia
Hyperphosphatemia
Hypocalcemia
Consequence of TLS
Renal failure
Hyperkalemia leads to
Cardiac and neuromuscular complications (cramps)
Hyperphosphotemia leads to
GI symptoms, lethargy and seizures
Hypocalcemia
Leads to cardiac arrhythmia, hypotension, tetany
Hydration + TLS
- Initiate 24-48 hours prior to therapy
- Continue until 48-72 hours after therapy
- Diuretics should be considered to have equal fluid intake and output
Alkalinize Urine + TLS
• Sodium bicarbonate or acetazolamide (inhibiters carbonic anhydrase → increases pH → increase solubility of uric acid)
GENERALLY NOT RECOMMENDED
Allopurinol MOA and Dose
Inhibits xanthine oxidase so it inhibits the formation of uric acid
Dose: LD of 600 mg and then 300 mg/day
Rasburicase MOA and Use
- Urate acid is converted to Allatoin via urate oxidase and is 5-10X more soluble than urate acid so it will get cleared quicker
- This prevents hyperuricemia and TLS